Drugmakers are starting early in developing biogenerics

08/16/2010 | Wall Street Journal, The

Despite an absence of specific guidelines from the FDA, companies including Pfizer and Hospira are wasting no time developing biogenerics to ensure they are in the forefront of the market. Hospira Chief Scientific Officer Sumant Ramachandra predicted that the guidance will not be finalized until next year, but an FDA spokeswoman said the agency has formed a task force to create detailed policy and procedures for approving generic versions of biotech drugs.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Teaching Associate (Hospitality Management)
University of Illinois at Urbana-Champaign
Urbana, IL
Director, Global Regulatory Affairs
Rodan and Fields, LLC
San Francisco, CA